RxDoctor Payments Data

Virgilio Ponferrada, MD

Urology · Piqua, OHNPI 1356447759

Payments from drug & device makers

$1,021in general payments, 2019–2025

Across 55 payments — averaging $18.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$385
  • Astellas Pharma US Inc$326
  • Pfizer$116
  • Johnson & Johnson$95
  • Merck$30
  • Dendreon Pharmaceuticals LLC$23
  • plus $47 from 4 others

What the payments were for

  • Food & beverage$90288%
  • Education$11912%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie18$385
Astellas Pharma US Inc17$326
Pfizer7$116
Johnson & Johnson5$95
Merck1$30
Dendreon Pharmaceuticals LLC1$23
Verity Pharmaceuticals Inc.1$17
Procept Biorobotics Corporation1$17
Bayer1$13
Innovative Medical Technologies, LLC3$0

How this compares

$1,021 in reported general payments places this provider in the 30th percentile of 485 urology providers in Ohio.

See all urology providers in Ohio

Medicare billing

Part B allowed, 2024
$131,646
Medicare patients
197
Services billed
891

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron33$28,591
Bethanechol Chloride29$1,651
Cephalexin214$855
Dutasteride14$781
Tamsulosin Hcl60$612
NitrofurantoinNitrofurantoin Macrocrystal13$550
Oxybutynin Chloride ErOxybutynin Chloride20$394
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen74$276
Allopurinol14$231
Levofloxacin20$99
Finasteride14$88
Ciprofloxacin Hcl19$74
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim18$60
Hyoscyamine Sulfate15$54

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$326$28,59133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 485 urology providers in Ohio.

Other urology in Piqua

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →